Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CTTI Recommendations Developed to Improve Investigator Retention

George Clinical
Posted on: 02 Nov 17

SYDNEY, AUSTRALIA (20 OCTOBER 2017) George Clinical, a leading CRO in Asia, is delighted to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Strengthening the Investigator Site Community. The recommendations to which George Clinical and their parent company, The George Institute for Global Health contributed, aims to encourage greater long-term engagement and participation by clinical site investigators.

The recommendations focus on strengthening four key categories of site-based research activity:

Developing site-based research infrastructure and staff;

Optimizing trial execution and conduct;

Improving site budget and contract negotiations; and

Discovering additional trials to conduct.

“George Clinical welcomes the recommendations released by the CTTI,” Dr Marisa Petersen, CEO of George Clinical said. “Our business of managing clinical trial programs is highly dependent on well- equipped and supported investigational sites. George Clinical has always believed that a greater emphasis on supporting the principal investigators, co-investigators and research coordinators will positively influence all aspects of site-based research activity. As such, we welcome the recommendations that highlight their contribution, along with providing a suite of other key components that are needed in order to support and retain investigators.”

The “Recommendations for Strengthening the Investigator Site Community” report stated that:

‘...evidence suggests that many investigators are leaving clinical research due to difficulty balancing workload, time requirements to conduct trials, data and safety reporting burdens, and financial issues... Substantial time and resources are needed to initiate and train new site investigators in clinical trial processes ... High attrition rates for U.S.-based investigators and the resultant need to initiate new investigators to sustain an adequate pool of investigators increase the costs of performing clinical trials and threaten the quality and efficiency of trial conduct.’

When asked about the impact of these recommendations, Dr Petersen adds:

“These recommendations are an important formal framework for the sector. George Clinical have embraced these recommendations noting that they align well with our unique integrated scientific leadership service, designed to provided peer to peer support for investigators. As the number of clinical trials increase in the Asia-Pacific, these clear and transparent guidelines will be a great asset and reassurance for sponsors looking to bring their compound into the world’s most dynamic market.”

About the Clinical Trial Transformation Initiative

The Clinical Trials Transformation Initiative (CTTI) co-founded by Duke University and the FDA is a public-private partnership whose mission is to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. The CTTI vision is a high quality clinical trial system that is patient-centered and efficient, enabling reliable and timely access to evidence-based therapeutic prevention and treatment options.

More information about the Clinical Trial Transformation Initiative and these recommendations, please visit their website:

About George Clinical

George Clinical is a leading independent Asia-Pacific based clinical research organisation (CRO) with global capabilities differentiated by scientific leadership, innovation and extensive investigator networks. With staff operating in 13 countries, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device and diagnostic customers, for all trial phases, registration and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery capability to create a distinctive world-class service.

George Clinical has grown from an academic group conducting trials to a CRO delivering clinical trial services primarily for industry but also academic researchers.

George Clinical provides a range of clinical services across a variety of therapeutic areas, predominantly in the areas of chronic disease: oncology, renal health, endocrinology, respiratory health, cardiovascular health, neurology and for the implementation of medical devices.

Editor's Details

Michael Sydes
George Clinical
+61 2 8052 4300

Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.